Online Discussion with Michael Osterholm: Coronavirus Spreads What’s New and the Path Forward, New America

[ONLINE] – Coronavirus Spreads
What’s New and the Path Forward
EVENT

Coronavirus, COVID-19, has rapidly spread and countries throughout the world are shuttering their economies and ordering people to stay at home to try and halt the spread. How is the effort going and what does the future hold?

Join the International Security Program via webcast as we welcome Michael T. Osterholm, PhD, MPH, director of the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. From June 2018 through May 2019, Dr. Osterholm served as a Science Envoy for Health Security on behalf of the US Department of State.

He is the author of the 2017 book, Deadliest Enemy: Our War Against Killer Germs, in which he not only details the most pressing infectious disease threats of our day but lays out a nine-point strategy on how to address them, with preventing a global flu pandemic at the top of the list.

In addition, Dr. Osterholm is a member of the National Academy of Medicine (NAM) and the Council of Foreign Relations. In June 2005 Dr. Osterholm was appointed to the newly established National Science Advisory Board on Biosecurity. In July 2008, he was named to the University of Minnesota Academic Health Center’s Academy of Excellence in Health Research and in October 2008, he was appointed to the World Economic Forum Working Group on Pandemics.

Previously, Dr. Osterholm served for 24 years (1975-1999) in various roles at the Minnesota Department of Health (MDH), the last 15 as state epidemiologist and chief of the Acute Disease Epidemiology Section. While at the MDH, Dr. Osterholm and his team were leaders in the area of infectious disease epidemiology.

Speaker:

Michael T. Osterholm, @mtosterholm
Director, Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota

Moderator:

Peter Bergen, @peterbergencnn
Vice President Global Studies & Fellows, New America

FULL ARCHIVE